23 results about "Ghrelin" patented technology

The invention relates to the technical field of medicines, in particular to application of a growth hormone releasing peptide Ghrelin receptor in itching intervention. By adjusting the activity of the receptor, the invention provides a new strategy for intervening pruritus: activation of the Ghrelin receptor can be used for inducing pruritus so as to construct a disease model; and inhibiting the Ghrelin receptor is used for preventing or treating pruritus, and the pruritus comprises acute pruritus and chronic pruritus. In specific implementation, the inhibition of the receptor is realized by applying the Ghrelin receptor antagonist, and the activation of the receptor is realized by applying the Ghrelin receptor agonist. Therefore, by targeting the Ghrelin receptor, controllable induction and efficient inhibition of pruritus are realized, mechanism innovation, treatment practicability and conversion feasibility are integrated, and a breakthrough strategy is provided for prevention and treatment of pruritus-related diseases.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme. The compositions and methods disclosed herein may be administered to mammals or mammalian cells for reducing drug-seeking behavior.

The present application provides a biological product and a method and an application thereof. The biological product is used for the preparation of a therapeutic agent for cancer treatment, and it includes at least one of the recombinant butyrylcholinesterase-albumin (rBChE-albumin) fusion protein and the recombinant butyrylcholinesterase-Fc (rBChE-Fc) fusion protein. The biological product adjusts the balance of acetylcholine and other related metabolic pathways by supplementing at least one of the exogenous rBChE-albumin fusion protein and rBChE-Fc fusion protein to treat cancer. The present invention solves the problem that the extraction and purification of BChE from human serum may not meet the huge demand for cancer treatment. The present application further provides a biological product for neutralizing and degrading nerve agents and organophosphate compounds, hydrolyzing ghrelin, and anti-wrinkle.

This invention belongs to the field of biomedical technology and discloses a specific structural lipase inhibitor that promotes ATGL activation, its preparation method, and its application. The inhibitor is derived from grape leaves. Through optimized extraction processes, the lipase inhibitory activity is significantly improved. The compound composition and structural ratio of the inhibitor are directionally enriched and clarified, resulting in a product with stable activity and controllable quality. Experiments have confirmed that the lipase inhibitor described in this application can simultaneously inhibit fat absorption and activate ATGL, forming a dual mechanism of action of "inhibiting absorption" and "inhibiting storage." It reduces TG, TC, LDL-C, LP, and FFA, upregulates HDL-C, stabilizes leptin, reduces ghrelin, and increases CCK and PYY, thereby effectively regulating lipid metabolism, controlling weight, improving blood lipids, and stabilizing blood sugar, with high safety.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

The present invention relates to a use of a triazole compound as a ghrelin receptor agonist and, more specifically, to a composition for preventing or treating diseases mediated by the ghrelin receptor, the composition being of a triazole compound which strongly binds to the ghrelin receptor with very high specificity. The compound provided by the present invention exhibits a strong binding force to the ghrelin receptor with very high specificity, and thus may be very usefully employed for preventing or developing a therapeutic agent for diseases mediated by the ghrelin receptor.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.

Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with mTBI, e.g. sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multiple consecutive days after the diagnosis of a mTBI, e.g. sustained mTBI.

The novel compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride has high permeability, is able to cross the blood-brain barrier and shows consistent ghrelin agonist activity at the level of the central nervous system; the compound is effective in the treatment and / or prevention of medical conditions mediated by ghrelin receptors in the central nervous system. In particular, in experimental tests, the compound shows high efficacy in the treatment of neurotoxic injuries and has an effective neuroprotective action combination pattern at both central and peripheral levels. The compound is also useful in the treatment of diseases requiring a reduction in heart rate. The compound has pharmacological activity at low to moderate doses, thus showing a good therapeutic index.

Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

The present application belongs to the technical field of biomarkers, and particularly relates to a system for evaluating the effectiveness of exercise intervention and application thereof. The present application finds through experiments that the Lac-Phe level in the stomach of obese patients is significantly reduced after exercise intervention, and other tissues have no significant change. Considering the role of the stomach in endocrine signal transduction, especially through ghrelin and other appetite-related hormones, this indicates that there is a potential interaction between Lac-Phe and the stomach pathway in regulating post-exercise satiety. Therefore, the expression level of Lac-Phe in the stomach tissue can be used as an effective index for evaluating the weight loss effect of exercise on obese patients.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating anorexia and weight loss, comprising a Bupleuri Radix extract. Specifically, the present invention provides a pharmaceutical composition having effects in preventing, ameliorating, or treating anorexia and weight loss, wherein a Bupleuri Radix extract increases ghrilin, which is a hormone that stimulates appetite, and decreases TPH1(I), which is a serotonin synthase. In addition, a health functional food for preventing or ameliorating anorexia and weight loss, comprising a Bupleuri Radix extract, can be developed, and the extract can be effectively used for the treatment and the development of therapeutic agents for anorexia induced by chemotherapy in the future.

The present disclosure relates to methods of treating diseases or conditions associated with fat tissue accumulation, such as obesity, metabolic syndrome, type II diabetes, and the like. Administration of a composition comprising a monoclonal antibody directed against a ghrelin. This results in a decrease in weight gain rate, and a significant reduction in lipid synthesis and accumulation.

The invention relates to the technical field of electrical stimulation regulation of nervous systems, in particular to an intelligent ear vagus nerve stimulation weight-losing instrument which is characterized by comprising a pair of host units, and each host unit is internally provided with a micro-current generator, a biological impedance sensor, a micro-control chip, a power module and a wireless or Bluetooth transmission module; the host unit comprises a V-shaped plastic gel stimulation head, the plastic gel stimulation head is attached to an auricular concha contour, and the biological impedance sensor monitors the attaching degree of the plastic gel stimulation head and the auricular concha contour in real time; the micro-current generator stimulates acupoints related to secretion of gastric starvation element and leptin in a auricular concha area through the plastic gel stimulation head to promote metabolism; the power module comprises a charging bin and a built-in rechargeable battery, and the built-in rechargeable battery is arranged in the host unit. The defects that a traditional medicine / operation weight reduction method is large in side effect, low in compliance and limited in application scene are overcome, and a non-invasive, portable and intelligent weight reduction scheme is provided.

The present invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-chiro-inositol or myo-inositol, or any pharmaceutically acceptable salt thereof, for the treatment or prevention of a condition, disease or condition in a subject in need thereof in response to stimulation of a starvation receptor. In particular, for the treatment and / or prevention of conditions responsive to positive modulation (stimulation) of the starvation receptor, such as diabetes, obesity-related conditions, and most preferably for the treatment or prevention of age-related conditions or diseases, such as obesity-related conditions. Enhancing muscle viability or fragility, and treating or preventing sarcopenia, improving cognition (and / or treating or preventing diseases such as Alzheimer's disease, vascular dementia, Parkinson's disease and huntington's disease), for example by promoting appetite, inhibiting insulin secretion and reducing insulin resistance, increasing growth hormone release, by increasing net muscle mass and treating or preventing age-related hypertension.

Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and / or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and / or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

To provide compositions for use in the treatment and / or prevention of disorders responsive to positive modulation of a ghrelin receptor, such as diabetes, obesity-related disorders, and most preferably for the treatment or prevention of age-related conditions or diseases, for example, by stimulating appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility, and the like.SOLUTION: Provided is a composition, pharmaceutical composition, or nutraceutical or food composition, or dietary supplement comprising D-pinitol, D-chiro-inositol and / or myo-inositol, or any salt thereof, for use in preventing or slowing the onset of the clinical manifestations of mild cognitive impairment or in preventing or slowing the onset of the clinical manifestations of a tauopathy in a subject.SELECTED DRAWING: None

The present invention relates to compounds of general formula I,wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.

The invention discloses a preparation method of a key intermediate of a macrocyclic auxin-releasing peptide receptor modulator, which comprises the following steps: by taking 3-(2-methoxyphenyl) propionic acid as a raw material, preparing 3-(2-methoxyphenyl) propionamide through substitution reaction, reducing the 3-(2-methoxyphenyl) propionamide into 3-(2-methoxyphenyl) propylamine, removing methoxy to prepare 2-(3-aminopropyl) phenol, and preparing the key intermediate of the macrocyclic auxin-releasing peptide receptor modulator. The preparation method comprises the following steps: preparing N-[3-(2-phenolic phenyl) propyl] phenylmethyl carbamate through a substitution reaction, carrying out a substitution reaction on the N-[3-(2-phenolic phenyl) propyl] phenylmethyl carbamate and methyl lactate, and finally reducing to generate N-[3-[2-[(1R)-2-hydroxy-1-methyl ethyoxyl] phenyl] propyl] phenylmethyl carbamate; the method has the advantages of mild reaction, high yield, high purity, environmental protection, safety and reliability, and can provide a macrocyclic auxin-releasing peptide receptor modulator key intermediate with abundant sources and low cost for preparation of related products in the field of biological medicine.

Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.